Sign in

You're signed outSign in or to get full access.

Christopher Uhde

Christopher Uhde

Senior Pharma & Biotech Equity Analyst at SEB

Sweden

Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, specializing in Nordic and European biotechnology and pharmaceutical companies, with a strong track record advising on successful IPOs and private placements. He has been involved in raising significant capital for leading firms, such as overseeing a €50 million placement at a €500 million valuation for an advanced Swedish regenerative medicine platform, and is recognized for his deep expertise in assessing public and private biotech opportunities. With a career rooted in pharmaceutical research and investment banking, Christopher leverages a scientific background—including a PhD—and experience across dynamic market cycles to help innovative companies scale and access capital markets. He is known for providing thought leadership on market trends and holds advanced finance and scientific credentials, though specific FINRA or securities licenses are not publicly listed.

Christopher Uhde's questions to ASTRAZENECA (AZN) leadership

Question · Q4 2025

Christopher Uhde asked about Calquence's growth prospects, specifically if the AMPLIFY regimen will significantly boost growth beyond current consensus estimates, and if there are other key events to unlock further growth.

Answer

Dave Fredrickson, EVP, Oncology Business Unit, AstraZeneca, confirmed AMPLIFY's importance for Calquence's growth, especially with anticipated US approval. He highlighted the trend towards finite therapies in hematology and Calquence's differentiated profile against venetoclax-based options. He also mentioned opportunities in ECHO for second-line MCL and DLBCL with Escalade.

Ask follow-up questions

Fintool

Fintool can predict ASTRAZENECA logo AZN's earnings beat/miss a week before the call

Question · Q4 2025

Christopher Uhde questioned the growth potential for Calquence, specifically whether the AMPLIFY regimen will significantly boost sales beyond current consensus estimates, and if there are other key events to unlock further growth.

Answer

Dave Fredrickson, EVP, Oncology Business Unit, highlighted AMPLIFY's importance for finite therapies, its differentiated profile against venetoclax, and its potential first-mover advantage in the US. He also mentioned opportunities in second-line MCL (ECHO) and DLBCL (Escalade) as future growth drivers.

Ask follow-up questions

Fintool

Fintool can write a report on ASTRAZENECA logo AZN's next earnings in your company's style and formatting

Christopher Uhde's questions to Alvotech (ALVO) leadership

Question · Q2 2025

Christopher Uhde of SEB inquired about Alvotech's confidence in its full-year 2025 guidance, the potential for further growth from the Cymlandi (Humira biosimilar) Qualant channel in the U.S., and whether the company plans to issue press releases on FDA inspection outcomes for its late-stage pipeline candidates.

Answer

CFO Linda Jónsdóttir stated that while H1 was strong, the company is not changing its guidance due to expected revenue lumpiness, with Q3 being soft and Q4 being much stronger. CCO Anil Okay added that the Qualant channel business is expected to continue, but the focus is on value over volume. CEO Róbert Wessman explained that FDA inspections are a normal part of business and the company will inform the market upon product approvals rather than after each inspection.

Ask follow-up questions

Fintool

Fintool can predict Alvotech logo ALVO's earnings beat/miss a week before the call